Akari Therapeutics, Plc (AKTX) Amount of Cash per Share

Akari Therapeutics' development of biologics for rare pathologies remains independent of economic cycles, as R&D processes are isolated from the macro environment. The cash per share trend, with the value fixed at 2.54, illustrates the burn rate of reserves. In the future, monopoly status in the orphan segment will provide pricing power, although the current lack of revenue and the anticipation of FDA approval render it zero.
Comprehensive metric breakdowns and analytics for Akari Therapeutics Plc (AKTX)

For Akari Therapeutics, which is developing an R&D pipeline to combat orphan diseases, the cash per share chart serves as an indicator of financial autonomy. This metric determines the volume of liquid assets attributable to a single common share. The calculation is based on daily monitoring of cash balances relative to the total number of issued securities. The current value of 2.54 demonstrates the company's ability to fund the development of nomacopan without emergency loans. The trend of this indicator allows for an assessment of the risk of equity dilution while preparing to bring the drug to market.